trazodone ↑ SSRIs (except sertraline)
↑ TCAs
↑ trazodone Careful dosage titration of the antidepressant and monitoring for antidepressant response are recommended when coadministered with GENVOYA.
Antifungals:
itraconazole
ketoconazole‡
voriconazole ↑ elvitegravir
↑ cobicistat
↑ itraconazole
↑ ketoconazole
↑ voriconazole When administering with GENVOYA, the maximum daily dosage of ketoconazole or itraconazole should not exceed 200 mg per day.
An assessment of benefit/risk ratio is recommended to justify use of voriconazole with GENVOYA.
Anti-gout:
colchicine ↑ colchicine GENVOYA is not recommended to be coadministered with colchicine to patients with renal or hepatic impairment.
Treatment of gout-flares – coadministration of colchicine in patients receiving GENVOYA:
0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (half tablet) 1 hour later. Treatment course to be repeated no earlier than 3 days.
Prophylaxis of gout-flares – coadministration of colchicine in patients receiving GENVOYA:
If the original regimen was 0.6 mg twice a day, the regimen should be adjusted to 0.3 mg once a day. If the original regimen was 0.6 mg once a day, the regimen should be adjusted to 0.3 mg once every other day.
Treatment of familial Mediterranean fever – coadministration of colchicine in patients receiving GENVOYA:
Maximum daily dosage of 0.6 mg (may be given as 0.3 mg twice a day).
Antimycobacterial:
rifabutin‡
rifapentine ↓ elvitegravir
↓ cobicistat
↓ TAF For contraindicated antimycobacterials, [see CONTRAINDICATIONS (4)]
Coadministration of GENVOYA with rifabutin or rifapentine is not recommended.
Antipsychotics:
e.g.,
perphenazine
risperidone
thioridazine
quetiapine ↑ antipsychotic
↑ quetiapine For contraindicated antipsychotics, [see CONTRAINDICATIONS (4)]
A decrease in dose of the antipsychotics that are metabolized by CYP3A or CYP2D6 may be needed when co-administered with GENVOYA.
Initiation of GENVOYA in patients taking quetiapine:
Consider alternative antiretroviral therapy to avoid increases in quetiapine exposure. If coadministration is necessary, reduce the quetiapine dose to 1/6 of the current dose and monitor for quetiapine-associated adverse reactions. Refer to the quetiapine prescribing information for recommendations on adverse reaction monitoring.
Initiation of quetiapine in patients taking GENVOYA:
Refer to the quetiapine prescribing information for initial dosing and titration of quetiapine.
Benzodiazepines:
e.g.,
Parenterally administered midazolam
clorazepate
diazepam
estazolam
flurazepam
lorazepam ↑ diazepam
↔ lorazepam
↑ midazolam Coadministration of GENVOYA with diazepam or parenterally administered midazolam should be done in a setting that ensures close clinical monitoring and appropriate medical management in case